Dermatomyositis Market Set to Advance with Improved Diagnosis and Emerging Immunotherapies by 2034
DelveInsight's ' Dermatomyositis Market Insight, Epidemiology, and Market Forecast – 2034 ' provides an in-depth analysis of the current landscape and future outlook of the DM market across major geographies, including the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. The report explores detailed epidemiological trends, segmentation by age and clinical subtypes, and diagnostic challenges that contribute to underreporting and delayed intervention.
Current treatment regimens typically include corticosteroids, immunosuppressants (methotrexate, azathioprine), intravenous immunoglobulin (IVIG), and emerging biologics like rituximab. However, response rates vary, and long-term use can lead to significant side effects. A growing pipeline of investigational agents—targeting pathways such as type I interferons and B-cell modulation—offers promising avenues for disease-specific and steroid-sparing therapies.
The Dermatomyositis market is projected to witness steady growth through 2034, fueled by increased disease recognition, clinical trial activity, and strategic advancements by pharmaceutical companies. Biotech firms and academic institutions are exploring novel immunomodulatory agents and precision medicine approaches to improve outcomes in both adult and pediatric populations.
DelveInsight's report is an essential resource for pharmaceutical executives, clinical researchers, investors, and healthcare professionals who seek strategic insights into the evolving DM landscape, from market dynamics and unmet needs to the competitive pipeline shaping the future of dermatomyositis care.
Some of the Key Facts of the Dermatomyositis Market Report:
• In 2023, the dermatomyositis market in the 7MM was valued at approximately USD 187 million, and is projected to grow at a CAGR of 16.8% due to improved disease awareness, diagnostics, and the introduction of new therapies.
• The U.S. had the highest number of diagnosed cases, with around 38.5K in 2023.
• Across the 7MM, there were nearly 72K diagnosed prevalent cases in 2023, with 91% in adults and 9% in juveniles.
• The U.S. accounted for ~54% of total diagnosed cases, while EU4 and the UK represented about 29%, and Japan ~17%.
• In January 2025, RESTEM announced that the FDA granted Fast Track designation for its Restem-L program, using umbilical cord outer lining stem cells (ULSCs) to treat Polymyositis and Dermatomyositis (PM/DM), now classified as Idiopathic Inflammatory Myopathy (IIM). This follows the recent Orphan Drug Designation for Restem-L in IIM.
• In July 2024, Priovant Therapeutics announced the completion of enrollment for its Phase 3 VALOR trial evaluating brepocitinib in dermatomyositis. With 241 participants across 90 sites on four continents, it is the largest interventional trial ever conducted for the condition.
• Leading companies in the Dermatomyositis market include Kezar Life Sciences, Argenx, Pfizer, CSL Behring, Viela Bio, PAEAN Biotechnology, Alexion Pharmaceuticals, and others.
• Emerging acute Dermatomyositis drugs include KZR-616, EFG PH20, PF 06823859, Hizentra, Daxdilimab, PN 101, Ravulizumab, and others.
• The increasing prevalence of dermatomyositis and ongoing advancements in therapeutic options are driving the demand for more effective treatment approaches.
To know in detail about the dermatomyositis market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Dermatomyositis Market Forecast
Dermatomyositis Overview
Dermatomyositis is a rare, systemic autoimmune disorder characterized by chronic inflammation of the skin and muscles. It presents with hallmark features such as symmetric proximal muscle weakness and distinctive skin rashes, including the heliotrope rash and Gottron's papules. The condition may also affect other organs, including the lungs, esophagus, and heart, and is sometimes associated with malignancy, especially in adults.
Dermatomyositis affects both adults and children (juvenile dermatomyositis), with varying severity. Its exact etiology remains unclear but is believed to involve a combination of genetic predisposition, immune system dysregulation, and environmental triggers. Diagnosis typically involves a combination of clinical findings, elevated muscle enzymes, electromyography (EMG), imaging studies, skin/muscle biopsies, and autoantibody testing.
Management of dermatomyositis requires a multidisciplinary approach, involving dermatologists, rheumatologists, neurologists, and physical therapists. While there is no cure, a range of therapies aim to control inflammation, alleviate symptoms, and prevent complications.
Get a free sample of the dermatomyositis market report with key insights and emerging therapies here:
Dermatomyositis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Dermatomyositis Epidemiology Segmentation:
The Dermatomyositis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:
• Diagnosed Dermatomyositis prevalence
• Type-specific Diagnosed Dermatomyositis prevalence
• Age-specific Diagnosed Dermatomyositis prevalence
• Gender-specific Diagnosed Prevalent Cases of Dermatomyositis
• Severity-specific Diagnosed Prevalent Cases of Dermatomyositis
• Chronicity-specific Diagnosed Prevalent Cases of Dermatomyositis
Download the report to understand which factors are driving dermatomyositis epidemiology trends @ Dermatomyositis Epidemiology Forecast
Dermatomyositis Drugs Uptake and Pipeline Development Activities
The Dermatomyositis drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the Dermatomyositis market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug.
Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share.
The report further delves into the Dermatomyositis pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies.
Dermatomyositis Market Outlook
While there is no definitive cure for dermatomyositis, available treatments aim to reduce inflammation, control symptoms, and improve quality of life. The approval of OCTAGAM and the development of multiple clinical management guidelines—such as those from the British Society for Rheumatology and the Japanese Society of Rheumatology—have significantly shaped and standardized the therapeutic landscape.
Treatment often begins with corticosteroids to manage muscle inflammation, followed by immunosuppressants or immunomodulators like methotrexate, azathioprine, or mycophenolate mofetil to reduce steroid dependency. For resistant or severe cases, advanced therapies such as rituximab, IVIG, and calcineurin inhibitors are employed.
In terms of skin manifestations, management includes both topical agents (e.g., corticosteroids, calcineurin inhibitors) and systemic medications like hydroxychloroquine. Adjunctive strategies such as physiotherapy, sun protection, and dietary interventions are also integral.
A growing pipeline featuring therapies like Brepocitinib (Priovant/Pfizer), Dazukibart (Pfizer), Efgartigimod (Argenx), and SAPHNELO (AstraZeneca) reflects an evolving research focus on immunomodulation and interferon signaling pathways. These emerging agents, combined with better diagnostics and increasing disease awareness, are expected to drive market growth through 2034.
Dermatomyositis Market Strengths
• A strong research focus on immune pathways (e.g., JAK-STAT, interferon) has led to promising investigational drugs such as Brepocitinib and Anifrolumab, indicating future therapeutic breakthroughs.
• Increasing awareness among clinicians and availability of diagnostic tools (e.g., autoantibody profiling, MRI) enable earlier diagnosis and more tailored treatment strategies.
Dermatomyositis Market Weaknesses
• Despite multiple treatment options, none offer a cure, and many patients experience relapses or partial responses, necessitating lifelong management.
• A significant portion of treatment regimens relies on off-label drug use, which lacks robust clinical trial data, leading to variable efficacy and safety outcomes across patient populations.
Scope of the Dermatomyositis Market Report
• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Dermatomyositis Companies: Kezar Life Sciences, Argenx, Pfizer, CSL Behring, Viela Bio, PAEAN Biotechnology, Alexion Pharmaceuticals, and others.
• Key Dermatomyositis Therapies: KZR-616, EFG PH20, PF 06823859, Hizentra, Daxdilimab, PN 101, Ravulizumab, and others.
• Dermatomyositis Therapeutic Assessment: Dermatomyositis, currently marketed, and Dermatomyositis emerging therapies
• Dermatomyositis Market Dynamics: Dermatomyositis market drivers and Dermatomyositis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Dermatomyositis Unmet Needs, KOL's views, Analyst's views, Dermatomyositis Market Access and Reimbursement
To learn more about the key players and advancements in the dermatomyositis treatment landscape, visit the Dermatomyositis Market Analysis Report
Table of Contents
1. Dermatomyositis Market Report Introduction
2. Executive Summary for Dermatomyositis
3. SWOT analysis of Dermatomyositis
4. Dermatomyositis Patient Share (%) Overview at a Glance
5. Dermatomyositis Market Overview at a Glance
6. Dermatomyositis Disease Background and Overview
7. Dermatomyositis Epidemiology and Patient Population
8. Country-Specific Patient Population of Dermatomyositis
9. Dermatomyositis Current Treatment and Medical Practices
10. Dermatomyositis Unmet Needs
11. Dermatomyositis Emerging Therapies
12. Dermatomyositis Market Outlook
13. Country-Wise Dermatomyositis Market Analysis (2020–2034)
14. Dermatomyositis Market Access and Reimbursement of Therapies
15. Dermatomyositis Market Drivers
16. Dermatomyositis Market Barriers
17. Dermatomyositis Appendix
18. Dermatomyositis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
33 minutes ago
- CTV News
Fast walking is a key to longevity, research shows
Practice good walking form and conscious breathing to get the most benefits from fast walking. TravelCouples//File via CNN Newsource Too busy to go to the gym? Don't worry — you can stay healthy by incorporating at least 15 minutes of fast walking into your everyday routine, new research suggests. In general, it's recommended that people commit to 150 minutes of moderate activity per week to see sufficient health benefits, said Dr. Wei Zheng, the study's corresponding author. But if 150 minutes is too difficult to manage, fast walking a minimum of 15 minutes every day can have the same health benefits. Zheng and a team of researchers recruited mostly low-income and Black study participants from 2002 to 2009, according to the study published in the American Journal of Preventative Medicine. The nearly 85,000 participants were given a comprehensive questionnaire about their exercise habits, average time spent working out, walking speed and health. Then the participants complete a questionnaire about 16 years later, and the analysis began in 2023. We know 'fast walking is good compared to slow walking,' but there isn't much research on how many minutes you should spend fast walking on average, said Zheng, director of the Vanderbilt Epidemiology Center and the Anne Potter Wilson Professor in Medicine at Vanderbilt University Medical Center in Nashville, Tennessee. On average, study participants who fast walked for at least 15 minutes every day saw a nearly 20% reduction in premature death compared with a 4% reduction among participants who walked slowly for a total of more than three hours a day. 'We've actually known for quite a long time that walking speed correlates with outcomes, meaning the faster you walk, the better you do. And it certainly makes sense, because you can imagine, somebody who's in really bad shape is probably not going to be able to walk very quickly,' said Dr. Andrew Freeman, director of cardiovascular prevention and wellness at National Jewish Health in Denver. He was not involved in the study. How walking can impact your health Walking has health benefits, such as managing weight and sugar intake, reducing risk of cancer, easing joint pain, and boosting immune function. Health experts 'know that when people are exercising regularly, blood vessels can relax and dilate a bit better. And then we also know that exercise is quite good for cholesterol, so it seems to lower cholesterol, and then overall, it reduces the risk of cancer and things that would otherwise hurt people,' Freeman said. Walking daily can also lower risk of dementia or cognitive decline in people predisposed to developing Alzheimer's, according to recent research. Engaging in daily physical activity, such as walking, promotes better sleep and reduces inflammation, which improves brain structure, according to the Piedmont Medical Center in South Carolina. 'I want to emphasize that these exercises, no matter slow or fast, all confirm some benefit,' Zheng said. 'But what we find is that fast walking as little as 15 minutes a day confirms substantiated benefits.' Fast walking has been found to have specific benefits, such as decreasing risk of heart failure, arrythmias and type 2 diabetes. '(T)he thought is that exercise has a very big effect on blood pressure, as you may know, and blood pressure, it is one of the more exponential risk factors that we have, for roughly every 20 points blood pressure goes above 120 (what is considered normal or healthy), the risk of a cardiac event roughly doubles,' Freeman said. 'So, it's a super potent and exponential risk factor, and we know that regular exercise lowers that.' Get your heart pumping In general, you can tell you're fast walking when you're able to talk but not sing, according to the United Kingdom's National Health Service. Alternatively, you can increase your walking pace by a couple of steps and track it with a metronome, according to a July study. 'I usually recommend that they get up before work, and they go for a brisk walk or a bike or a swim, or they do some high-intensity interval training, whatever it is that they're into,' Freeman said. People can go to 'a rec center, or they walk outside, if it is safe, or whatever it may be, and just weave it into their day.' Following good walking form, such as standing tall with your shoulders back and swinging your arms, can help prevent backaches, make it easy to breath and keep you balanced. 'Walking is a full body movement. It is not just about your lower body. It's not just one step in front of the one foot in front of the other,' said Dana Santas, a certified strength and conditioning specialist and mind-body coach in professional sports, in a previous article. 'Your arm swing is a huge part involved in the mechanics of walking. So, you want to have an arm swing that's coordinated with your foot movement, so it's opposing,' she added. Want to take it up a notch? When doing any form of exercise, try to practice conscious or nasal breathing, which is when you inhale through your nose and exhale through your mouth. This helps regulate blood pressure and can prevent hypertension, according to Santas. By Gina Park, CNN
Globe and Mail
an hour ago
- Globe and Mail
When a Healthcare Giant Gets Sick: Elevance Health's 20% YTD Decline
Elevance Health, Inc. ELV has endured a bruising 2025 so far, sliding 20.3% year to date and lagging both its industry peers and the S&P 500 Index. Shares closed Friday at $293.99, hovering just above the lower edge of their 52-week range of $273.71–$567.26. For value hunters, the stock's current level may look like an attractive entry point into a leading health benefits player; after all, buying closer to the low than the high has its appeal, right? Based in Indianapolis, IN, Elevance carries a market capitalization of $66.2 billion. Its peers like UnitedHealth Group Incorporated UNH and Centene Corporation CNC have also stumbled this year, in some cases even more sharply. In fact, UnitedHealth's sheer weight in the health insurance space has dragged down the sector on multiple occasions, while Centene has also contributed to the selling pressure. Price Performance – ELV, UNH, CNC, Industry & S&P 500 What's Dragging Down ELV Stock? Several headwinds are hitting Elevance simultaneously. Medicaid membership has shrunk 15.1% in 2024 and another 4.1% in the first half of 2025, erasing members and the revenues they bring. Medicare Supplement and employer group risk-based memberships in the commercial business are also slipping. The situation is likely to remain choppy into 2026, especially with the GOP's recently passed tax-and-policy package, which slashes Medicaid funding and overhauls Affordable Care Act eligibility and enrollment rules. Meanwhile, medical costs are climbing as utilization grows, compressing margins. In the second quarter, the company's benefit expense ratio worsened 260 basis points year over year to 88.9%. Full-year benefit expense ratio is expected at approximately 90%, with the second half likely to witness steeper jumps. Investor sentiment soured further as management cut its full-year 2025 outlook. The company now expects adjusted EPS to be around $30, lower than the previously forecasted range of $34.15-$34.85, down from the 2024 reported figure of $33.04. Its peers, such as UnitedHealth and Centene, also lowered their expectations for the current year. Adding to the unease, President Donald Trump's sharp criticism of pharmacy benefit managers (PBMs) in his push to lower drug prices has put companies with PBM exposure — including Elevance, UnitedHealth and Cigna — under a regulatory and political cloud. Centene sidestepped potential trouble by exiting its PBM operations a few years ago, executing the move as part of its broader value-creation strategy. Analysts Turn Cold for ELV Over the past month, 2025 and 2026 earnings estimates have each seen double-digit downward revisions, 16 and 14 cuts, respectively, with no upgrades in sight. The current Zacks Consensus Estimate calls for 2025 EPS of $30.59, a 7.4% decline from the prior year, despite revenue projections implying a 12.4% gain. The company's earnings track record has been mixed, beating expectations twice in the past four quarters but missing twice as well, for an average surprise of negative 2.3%. Elevance Health, Inc. Price, Consensus and EPS Surprise Elevance Health, Inc. price-consensus-eps-surprise-chart | Elevance Health, Inc. Quote ELV's Valuation: Cheap, But for a Reason? At a forward 12-month P/E of 9.24X, Elevance Health trades well below both its five-year median of 13.44X and the industry average of 14.32X, a valuation gap that reflects investor caution. UnitedHealth and Centene, despite suffering steeper sell-offs, command higher multiples of 14.05X and 9.94X, respectively. Why the Long Game Still Works Despite the near-term turbulence, Elevance retains solid long-term growth levers. Product expansion, revenue diversification, rate hikes, and selective growth in commercial lines should help offset pressures. Premium increases and a sharper focus on optimizing the government business position the company to benefit from structural healthcare trends, including rising health spending, an aging population and the growing burden of chronic disease. The company reallocates resources to more profitable areas and makes prudent acquisitions. ELV's return on invested capital of 9.36% is higher than the industry average of 5.80%, which indicates that the company is more efficient in generating returns from its capital than the industry. Its consistent dividend payouts and stock repurchases boost shareholders' value. Elevance's dividend yield of 2.33% is higher than the industry average of 1.37%. ELV bought back shares worth $379 million in the second quarter alone. It had a leftover capacity of roughly $8 billion under its share buyback authorization as of June 30, 2025. To Conclude While Elevance's beaten-down valuation and strong long-term industry tailwinds might tempt bargain hunters, the near-term outlook remains clouded by shrinking memberships, rising medical costs, regulatory risks and deteriorating analyst sentiment. With earnings estimates moving sharply lower and the stock currently carrying a Zacks Rank #5 (Strong Sell), investors may want to stay on the sidelines until the company's fundamentals show clearer signs of recovery. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. See our %%CTA_TEXT%% report – free today! 7 Best Stocks for the Next 30 Days Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Centene Corporation (CNC): Free Stock Analysis Report Elevance Health, Inc. (ELV): Free Stock Analysis Report
National Post
5 hours ago
- National Post
Japan boxing to hold emergency meeting following deaths of two boxers
Japanese boxing officials will hold an emergency meeting on Tuesday as the sport in the country faces intense scrutiny following the deaths of two fighters in separate bouts at the same event. Article content Super featherweight Shigetoshi Kotari and lightweight Hiromasa Urakawa, both 28, fought on the same card at Tokyo's Korakuen Hall on August 2 and died days later following brain surgery. Article content Article content Article content The Japan Boxing Commission (JBC), gym owners and other boxing officials are under pressure to act and will hold an emergency meeting on Tuesday. Article content They are also expected to have talks about safety next month, local media said. Article content 'We are acutely aware of our responsibility as the manager of the sport,' Tsuyoshi Yasukochi, secretary-general of the JBC, told reporters on Sunday. Article content 'We will take whatever measures we can.' Article content Japanese media highlighted the risks of fighters dehydrating to lose weight rapidly before weigh-ins. Article content 'Dehydration makes the brain more susceptible to bleeding,' the Asahi Shimbun newspaper said. Article content That is one of the issues the JBC plans to discuss with trainers. Article content 'They want to hear from gym officials who work closely with the athletes about such items as weight loss methods and pre-bout conditioning, which may be causally related (to fatalities),' the Nikkan Sports newspaper said. Article content In one immediate measure, the commission has decided to reduce all Oriental and Pacific Boxing Federation title bouts to 10 rounds from 12. Article content
